Shilin Xu

10PUBLICATIONS
10CO-AUTHORS
Molecular medicineCheminformatics and quantitative structure-activity relationshipsMedical molecular engineering of nucleic acids and proteinsGlycoconjugatesMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Nov 17, 2025
Furo[2,3-f]quinazolin-7(6H)-one Derivatives as Potent, Selective, and Orally Bioavailable MAT2A Inhibitors for MTAP-Deficient Cancer Therapy.

Zihan Shi, Kexin Lin, Lijie Lin

|Sep 25, 2025
Proteome-Wide Ligand and Target Discovery by Using Covalent Probes and Natural Products.

Jingqing Liu, Chaoming Huang, Shengrong Li

|Aug 21, 2025
Recent advances in small molecules targeting the METTL3.

Feifei Wu, Lei Yu, Shilin Xu

|Jan 02, 2025
Targeting QPCTL: An Emerging Therapeutic Opportunity.

Lei Yu, Yaoliang Sun, Longyan Xie

|Dec 28, 2024
Discovery of an Efficacious RET PROTAC Degrader with Enhanced Antiproliferative Activity against Resistant Cancer Cells Harboring RET Solvent-Front Mutations.

Qian Zhang, Yingqi He, Danni Rao

|Feb 22, 2024
Discovery of Pyrido[2,3-d]pyrimidin-7-one Derivatives as Highly Potent and Efficacious Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Inhibitors for Cancer Treatment.

Yaoliang Sun, Manman Chen, Yuyan Han

Pageof 2

Frequent Collaborators

2 joint publications

Shaomeng Wang

2 joint publications

Xingxing Diao

1 joint publications

Ke Zheng

1 joint publications

Bing Xiong